HELEN DINH: Open Payments
NPI 1255055422 · CAMPBELL, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,022 in 32 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $696 · 2025 $1,022
Food & beverage: $1,022
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 10 | $351 |
| Eisai Inc. | 7 | $271 |
| AstraZeneca Pharmaceuticals LP | 5 | $108 |
| BLUEWIND MEDICAL | 3 | $82 |
| ABBVIE INC. | 2 | $54 |
| Smith+Nephew, Inc. | 1 | $48 |
| Hologic Sales and Service, LLC | 1 | $35 |
| Baxter Healthcare | 1 | $31 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $25 |
| BIOTISSUE HOLDINGS INC. | 1 | $18 |
Products named: GEMTESA, Lenvima, REVI, BOTOX, LYNPARZA, STRAVIX, MYFEMBREE, ACESSA PROVU SYSTEM.
Industry payments across CA — which companies pay providers there.
